eligibility_summary
Inclusion: MM with failed curative options, >=2 prior regimens without CR or high-risk MM in CR1/CR2 not eligible for SCT, PFI <1 year, relapsed after SCT or residual disease and ineligible for SCT, expected survival >12 weeks, adequate organ function (Cr<2.5, AST/ALT<3x ULN, bilirubin<2.0), eligible for leukapheresis, consent. Exclusion: pregnant/lactinating, uncontrolled infection, active HBV/HCV or HIV, systemic steroids, prior CAR-T, uncontrolled comorbidity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06006741 (Phase 1). Intervention: MM-specific universal CAR T cells (biological, off-the-shelf allogeneic cellular immunotherapy) using several 4SCAR designs directed at different antigens. Mechanism of action: Patient receives gene-modified T cells expressing chimeric antigen receptors that bind tumor antigens and activate T-cell signaling (CD3ζ with co-stimulation), leading to targeted cytotoxicity and cytokine release against myeloma cells, aims for rapid availability and persistence despite poor autologous T-cell quality. Targets (cells/pathways): Malignant plasma cells in multiple myeloma via BCMA (TNFRSF17), CD138 (syndecan‑1), CD38, and CD19, expected on-target depletion of myeloma cells (and potentially normal B/plasma cells).